United Therapeutics presents positive data from ongoing research at the American Thoracic Society’s International Conference, May 15-20, Orlando (US)

United Therapeutics announced positive data from the TETON-1 phase 3 pivotal study of inhaled treprostinil in idiopathic pulmonary fibrosis (IPF), and of the ADVANCE OUTCOMES and ARTISAN studies on pulmonary arterial hypertension at the American Thoracic Society’s International Conference on May 15-20, in Orlando (see also our previous article at this link) The following posters […]

United Therapeutics presents positive data from ongoing research at the American Thoracic Society’s International Conference, May 15-20, Orlando (US) Read Post »

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026

Welcome to our April roundup of the most relevant and interesting content shared on this platform. April 2026 has been a particularly rich month, with significant news on the diagnostics, clinical trials and treatment front alongside important research on quality of life, patient preferences information, economic burden. There is also a selection of patient resources

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026 Read Post »

AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension with Interstitial Lung Disease (ILD-PH), April 9, 2026

AllRock Bio has dosed the first patients in its Phase 2a ROCSTAR trial, evaluating ROC-101 — a potential first-in-class oral pan-rho-associated protein kinase (ROCK) inhibitor — in patients with pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease. The open-label, multicenter, exploratory study will evaluate the safety, tolerability, and efficacy of ROC-101 in both

AllRock Bio Doses First Patients in Phase 2a Trial of ROC-101 for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension with Interstitial Lung Disease (ILD-PH), April 9, 2026 Read Post »

Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease 

Cereno Scientific has expanded the development focus of its oral HDAC inhibitor CS014 to include pulmonary hypertension associated with interstitial lung disease (PH-ILD), a severe condition with very limited treatment options and high unmet medical need. Originally developed for idiopathic pulmonary fibrosis (IPF), CS014 targets shared disease mechanisms including vascular remodeling, fibrosis, thrombosis, and inflammation—making

Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease  Read Post »

Phase 2 PHocus trial of mosliciguat completes enrollment in pulmonary hypertension associated with interstitial lung disease PH-ILD, Pulmonary Hypertension News, February 9, 2026

The February 9 2026 edition of Pulmonary Hypertension News reports that enrollment has been completed in under a year for the PHocus Phase 2 clinical trial testing mosliciguat, a once-daily inhaled therapy for pulmonary hypertension associated with interstitial lung disease (PH-ILD)—a condition where current treatment options remain limited and often poorly tolerated. Developed by Pulmovant,

Phase 2 PHocus trial of mosliciguat completes enrollment in pulmonary hypertension associated with interstitial lung disease PH-ILD, Pulmonary Hypertension News, February 9, 2026 Read Post »

First clinical site now open for large trial testing seralutinib for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), Pulmonary Hypertension News, November 7, 2025

The first clinical site is now active for a global Phase 3 study that will evaluate Gossamer Bio’s therapy candidate seralutinib for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study, titled SERANATA, aims to enroll around 480 patients aged 18 to 80, randomised to receive either 90 mg or 120 mg

First clinical site now open for large trial testing seralutinib for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), Pulmonary Hypertension News, November 7, 2025 Read Post »

TRANSLATE »
Scroll to Top